Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Katharina Versmold"'
Autor:
Katharina Versmold, Ferras Alashkar, Carina Raiser, Richard Ofori‐Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, Alexander Röth
Publikováno v:
European Journal of Haematology.
Objective: Describe the real-world clinical profile of eculizumab-treated patients by characterizing their short- and long-term clinical and laboratory outcomes. Methods: This retrospective study used preexisting medical records of eculizumab-treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83683880ba3a906f88903fe2b38466e1
https://doi.org/10.1111/ejh.13970
https://doi.org/10.1111/ejh.13970
Autor:
Pablo Katz, Carina Raiser, Alexander Roeth, Richard Ofori-Asenso, Katharina Versmold, Yutong Liu, Aijing Shang, Tao Xu, Ferras Alashkar
Background: Eculizumab, an anti-C5 antibody, was approved for the treatment of patients (pts) with symptomatic paroxysmal nocturnal hemoglobinuria (PNH) in 2007 and has been the standard of care for over a decade. However, published data on real-worl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b97d57a460cf2879b7d69e8f4f38f66
Autor:
Carina Raiser, Katharina Versmold, Aijing Shang, Tao Xu, Alexander Röth, Imi Faghmous, Pablo Katz
Publikováno v:
Blood. 136:38-39
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a life-threatening disease of dysregulated complement activation. It is a rare disease with an estimated incidence of 1 to 1.5 cases per million people globally. Eculizumab is a humanized monocl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87d111a5df9ea361d62d78c5966ee783
https://doi.org/10.1182/blood-2020-140693
https://doi.org/10.1182/blood-2020-140693